For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo ...

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Tesla Posts Weak Earnings, Joins Visa, Deutsche Bank And Other Big ...

Given the large stake in the stock by institutions, Geron's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 10 shareholders Ownership research ...

In the preceding three months, 4 analysts have released ratings for Geron GERN, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...

Geron (GERN) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the approval of Rytelo for the treatment of ...

In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against the other stocks. Ten companies kicked off this week’s trading mirroring a decline on Dow Jones ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...